Sterile Injectable Manufacturing: SOP for Impurity Profiling of Sterile Products – V 2.0

Posted on By

Sterile Injectable Manufacturing: SOP for Impurity Profiling of Sterile Products – V 2.0

Standard Operating Procedure for Impurity Profiling of Sterile Products


Department Sterile Injectable Manufacturing
SOP No. SOP/SIM/162/2025
Supersedes SOP/SIM/162/2022
Page No. Page 1 of 15
Issue Date 24/06/2025
Effective Date 26/06/2025
Review Date 24/06/2026

1. Purpose

This SOP outlines the standard procedures for profiling impurities in sterile injectable pharmaceutical products. It includes identification, quantification, classification, and reporting of impurities using validated analytical methods to ensure safety, efficacy, and compliance with pharmacopeial and ICH guidelines.

2. Scope

This SOP

is applicable to the Quality Control (QC) department involved in testing of all sterile injectable products manufactured at the facility. It covers routine analysis, stability studies, and investigational impurity profiling.

3. Responsibilities

  • QC Analyst: Execute impurity profiling tests and ensure accurate documentation.
  • QC Supervisor: Review test data and interpret results for regulatory compliance.
  • QA Department: Approve reports, investigate OOS/OOT results, and ensure SOP adherence.
  • Instrument Technician: Ensure instruments like HPLC and GC are calibrated and operational.
See also  Quality Assurance: SOP for Root Cause Analysis in QA Investigations - V 2.0

4. Accountability

The Head – Quality Control is accountable for the execution, review, and documentation of impurity profiling activities.

5. Procedure

5.1 Impurity Classification

  1. Organic Impurities – process-related or degradation products
  2. Inorganic Impurities – reagents, ligands, heavy metals
  3. Residual Solvents – as per ICH Q3C guidelines

5.2 Instrumentation and Equipment

  • HPLC system with UV/ELSD/RI/PDA detectors
  • Gas Chromatograph with FID/TCD
  • Analytical Balance (0.1 mg accuracy)
  • pH meter, Sonicator, Auto-sampler
  • Validated software for data acquisition (e.g., Empower, Chromeleon)

5.3 Reference Standards

  1. Use pharmacopeial or certified in-house reference standards.
  2. Store under recommended conditions (Annexure-1: Reference Standard Log).
  3. Document usage and expiry verification in test worksheet.

5.4 Sample Preparation

  1. Withdraw required volume (as per method) of sample under aseptic conditions.
  2. Filter through 0.22 μm membrane if required.
  3. Prepare blanks, standards, and spiked recovery solutions.

5.5 Analytical Testing

5.5.1 Organic Impurity Profiling (HPLC)

  1. Set column temperature, flow rate, and mobile phase as per validated method.
  2. Inject blank, standard, sample, and recovery solution.
  3. Calculate % impurities and total impurities.
See also  Formulation Development: SOP for Documentation in Product Development - V 2.0

5.5.2 Residual Solvent Analysis (GC)

  1. Prepare standard and sample vials with internal standard.
  2. Inject into GC with appropriate column (e.g., DB-624).
  3. Quantify residual solvents per ICH Q3C limits.

5.5.3 Inorganic Impurity Analysis

  1. Use appropriate colorimetric method or ICP-MS if applicable.
  2. Record observations and confirm results against specification.

5.6 Acceptance Criteria

  • Total impurities < NMT 2.0%
  • Any unidentified impurity < NMT 0.2%
  • Any individual known impurity < NMT 0.5%
  • Residual solvents: Class I – NMT 2 ppm, Class II/III – as per ICH

5.7 OOS/OOT Handling

  1. Initiate deviation and investigation as per QA protocol.
  2. Reanalyze sample if required, under QA supervision.
  3. Document final disposition based on risk assessment.

5.8 Documentation

  1. Record all chromatograms, observations, and peak integrations in Annexure-2: Test Data Sheet.
  2. Compile a summary report (Annexure-3) with chromatographic data and interpretations.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • QC: Quality Control
  • QA: Quality Assurance
  • HPLC: High Performance Liquid Chromatography
  • GC: Gas Chromatography
  • FID: Flame Ionization Detector
  • OOS: Out of Specification
  • OOT: Out of Trend
See also  Sterile Injectable Manufacturing: SOP for Handling Sterile Components during Manufacturing - V 2.0

7. Documents

  1. Reference Standard Log – Annexure-1
  2. Test Data Sheet – Annexure-2
  3. Impurity Profiling Report – Annexure-3

8. References

  • ICH Q3A/B – Impurities in New Drug Substances/Products
  • ICH Q2(R1) – Validation of Analytical Procedures
  • USP/NF General Chapters <621>, <467>

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation QC Analyst QA Executive Head QA
Department Quality Control Quality Assurance Quality Assurance

11. Annexures

Annexure-1: Reference Standard Log

Standard Name Lot No. Expiry Date Storage Checked By
Impurity A IMPA-011 15/08/2026 2–8°C S. Sridhar

Annexure-2: Test Data Sheet

Sample ID Impurity RT (min) Area % Status
INJ1202 Impurity B 4.22 0.38 Pass

Annexure-3: Impurity Profiling Report

Batch No. Total Impurities (%) Unidentified (%) Decision Reviewer
B240612 1.56 0.12 Complies Neha T.

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial Release New SOP QA Head
24/06/2025 2.0 Included residual solvent and impurity reporting formats Annual SOP Review QA Head
Injectables V 2.0 Tags:, , , , , , , , , , , , , , , , , , ,